157 related articles for article (PubMed ID: 27159786)
1. The value of demonstration projects for new interventions: The case of human papillomavirus vaccine introduction in low- and middle-income countries.
Howard N; Mounier-Jack S; Gallagher KE; Kabakama S; Griffiths UK; Feletto M; LaMontagne DS; Burchett HE; Watson-Jones D
Hum Vaccin Immunother; 2016 Sep; 12(9):2475-7. PubMed ID: 27159786
[TBL] [Abstract][Full Text] [Related]
2. What works for human papillomavirus vaccine introduction in low and middle-income countries?
Howard N; Gallagher KE; Mounier-Jack S; Burchett HED; Kabakama S; LaMontagne DS; Watson-Jones D
Papillomavirus Res; 2017 Dec; 4():22-25. PubMed ID: 29179865
[TBL] [Abstract][Full Text] [Related]
3. Human papillomavirus (HPV) vaccine coverage achievements in low and middle-income countries 2007-2016.
Gallagher KE; Howard N; Kabakama S; Mounier-Jack S; Burchett HED; LaMontagne DS; Watson-Jones D
Papillomavirus Res; 2017 Dec; 4():72-78. PubMed ID: 29179873
[TBL] [Abstract][Full Text] [Related]
4. Costs of introducing and delivering HPV vaccines in low and lower middle income countries: inputs for GAVI policy on introduction grant support to countries.
Levin A; Wang SA; Levin C; Tsu V; Hutubessy R
PLoS One; 2014; 9(6):e101114. PubMed ID: 24968002
[TBL] [Abstract][Full Text] [Related]
5. Lessons learnt from human papillomavirus (HPV) vaccination in 45 low- and middle-income countries.
Gallagher KE; Howard N; Kabakama S; Mounier-Jack S; Griffiths UK; Feletto M; Burchett HED; LaMontagne DS; Watson-Jones D
PLoS One; 2017; 12(6):e0177773. PubMed ID: 28575074
[TBL] [Abstract][Full Text] [Related]
6. Implementation of human papillomavirus immunization in the developing world.
Kane MA; Serrano B; de Sanjosé S; Wittet S
Vaccine; 2012 Nov; 30 Suppl 5():F192-200. PubMed ID: 23199963
[TBL] [Abstract][Full Text] [Related]
7. Human papillomavirus vaccine introduction--the first five years.
Markowitz LE; Tsu V; Deeks SL; Cubie H; Wang SA; Vicari AS; Brotherton JM
Vaccine; 2012 Nov; 30 Suppl 5():F139-48. PubMed ID: 23199957
[TBL] [Abstract][Full Text] [Related]
8. Human papillomavirus vaccine delivery in Mozambique: identification of implementation performance drivers using the Consolidated Framework for Implementation Research (CFIR).
Soi C; Gimbel S; Chilundo B; Muchanga V; Matsinhe L; Sherr K
Implement Sci; 2018 Dec; 13(1):151. PubMed ID: 30545391
[TBL] [Abstract][Full Text] [Related]
9. Upgrading public health programs for human papillomavirus prevention and control is possible in low- and middle-income countries.
Steben M; Jeronimo J; Wittet S; Lamontagne DS; Ogilvie G; Jensen C; Smith J; Franceschi S
Vaccine; 2012 Nov; 30 Suppl 5():F183-91. PubMed ID: 23199962
[TBL] [Abstract][Full Text] [Related]
10. Progress in HPV vaccination in low- and lower-middle-income countries.
LaMontagne DS; Bloem PJN; Brotherton JML; Gallagher KE; Badiane O; Ndiaye C
Int J Gynaecol Obstet; 2017 Jul; 138 Suppl 1():7-14. PubMed ID: 28691329
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus (HPV) vaccine implementation in low and middle-income countries (LMICs): health system experiences and prospects.
Wigle J; Coast E; Watson-Jones D
Vaccine; 2013 Aug; 31(37):3811-7. PubMed ID: 23777956
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges.
Poljak M
Clin Microbiol Infect; 2012 Oct; 18 Suppl 5():64-9. PubMed ID: 22862799
[TBL] [Abstract][Full Text] [Related]
13. Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006-January 2008.
Koulova A; Tsui J; Irwin K; Van Damme P; Biellik R; Aguado MT
Vaccine; 2008 Dec; 26(51):6529-41. PubMed ID: 18805453
[TBL] [Abstract][Full Text] [Related]
14. Present status of human papillomavirus vaccine development and implementation.
Herrero R; González P; Markowitz LE
Lancet Oncol; 2015 May; 16(5):e206-16. PubMed ID: 25943065
[TBL] [Abstract][Full Text] [Related]
15. HPV vaccination: The most pragmatic cervical cancer primary prevention strategy.
Sankaranarayanan R
Int J Gynaecol Obstet; 2015 Oct; 131 Suppl 1():S33-5. PubMed ID: 26433502
[TBL] [Abstract][Full Text] [Related]
16. Female human papillomavirus (HPV) vaccination: global uptake and the impact of attitudes.
Hopkins TG; Wood N
Vaccine; 2013 Mar; 31(13):1673-9. PubMed ID: 23375978
[TBL] [Abstract][Full Text] [Related]
17. Benefits of catch-up in vaccination against human papillomavirus in medium- and low-income countries.
Baussano I; Lazzarato F; Ronco G; Dillner J; Franceschi S
Int J Cancer; 2013 Oct; 133(8):1876-81. PubMed ID: 23564420
[TBL] [Abstract][Full Text] [Related]
18. Approaches to monitoring biological outcomes for HPV vaccination: challenges of early adopter countries.
Wong CA; Saraiya M; Hariri S; Eckert L; Howlett RI; Markowitz LE; Brotherton JM; Sinka K; Martinez-Montañez OG; Kjaer SK; Dunne EF
Vaccine; 2011 Jan; 29(5):878-85. PubMed ID: 20971113
[TBL] [Abstract][Full Text] [Related]
19. Human Papillomavirus Vaccination Coverage Among School Girls in a Demonstration Project - Botswana, 2013.
Raesima MM; Forhan SE; Voetsch AC; Hewitt S; Hariri S; Wang SA; Pelletier AR; Letebele M; Pheto T; Ramogola-Masire D; El-Halabi S
MMWR Morb Mortal Wkly Rep; 2015 Oct; 64(40):1147-9. PubMed ID: 26468997
[TBL] [Abstract][Full Text] [Related]
20. HPV vaccinations in low- and middle-income countries.
Bannazadeh Baghi H; Aghazadeh M
Am J Infect Control; 2018 Feb; 46(2):244. PubMed ID: 29217188
[No Abstract] [Full Text] [Related]
[Next] [New Search]